

Young EPLAW 2024

Program

Sunday 28 April 2024

19.00 – 23.00 Social event @ The Merode (place Poelaert 6, 1000 Brussels)

Monday 29 April 2024

9.00 - 16.30	Conference @ The Hotel (boulevard de Waterloo 8, 1000 Brussels)
--------------	---

Time	Agenda	Speakers
09:00	Registration, morning coffee	-/-
09:30	Welcome, opening remarks	Cordula Schumacher, President of EPLAW
09:45	Debriefing mock trial	Philippe Campolini, Secretary of EPLAW
10.00	Keynote speech	Stefan Johansson, Head of the Nordic Baltic Regional Division of the UPC
10.30	 The first year of UPC: notable cases and practical experiences (1.00) 1. Brief introduction on speaker and topics 2. Preliminary Injunctions: Presentation of relevant PI cases: factors considered in denying/granting/lifting PI applications, including the relevance of the prosecution history in claim construction 3. Measures to Preserve Evidence and/or Inspect Premises: Presentation of purpose of measures to preserve evidence and/or inspect premises and relevant UPC orders and factors considered in granting such measures; strategic considerations on the importance of such measures for a successful infringement case 4. Transparency: Introduction of rules on public access to court documents at the UPC and presentation of relevant cases: different approaches when interpreting Rule 262 and recent UPC Court of Appeal ruling on 	Chiara Centola (Trevisan & Cuonzo, IT - Chair), Ronja Schregle (Bardehle Pagenberg, DE) Giulia Pasqualetto (BonelliErede, IT) Clara Berrisch (Hoyng Rokh Monegier, DE)

	"reasoned request", discussion on balance between transparency/open justice principle;	
	5. Language of Proceedings: Brief introduction of rules governing language of proceedings at the UPC, data on languages currently used in infringement proceedings and presentation of relevant cases where a switch of the existing languages of proceedings to English was ordered, discussion on latest trend and practice	
11:30	Coffee break (0.15)	-/-
11:45	 The Draft EU SEP Regulation (1.00) Brief introductory presentation followed by panel discussion Intro - 'teach-in' part 1: What are SEPs & FRAND; why are they relevant? Wireless comms, video codecs = connected world Connected health/med-tech (cross-practice) Unique IP environment Intro - 'teach-in' part 2: What is the Regulation now being proposed? What is it supposed to achieve and why? Relief - injunctions and FRAND determination Current procedure: Availability of German injunctions UK global rate setting 'Willingness' How are these addressed in the Reg & how will this impact national practitioners? 	Sven Krause (Hoyng Rokh Monegier, DE – Chair) Federico Manstretta (Bird & Bird, IT) Ettore Fassina (Jacobacci Avvocati, IT) Ethan Plumb (Osborne Clarke, UK) Nadine Bleach (Bristows, UK) Mari Sierra (Wilmer Hale, UK)
	 What is the situation now? Patents, rates & comparable licences Essentiality/technical merits How are these addressed in the Reg & how will this impact national practitioners? 	
12.45	Lunch (1.15)	-/-
14.00	Updates on plausibility (1.00)	Introduction:
	Part 1 (15 minutes) – Introduction Introduction to plausibility and its relevance for the patentability requirements, the G 2/21 decision, and shortly on the apixaban proceedings	Matthew White (Osborne Clarke, UK) Sab Singh (Freshfields, UK) <i>Panel:</i> Inés Molina (Perez-Llorca,
	Part 2 (45 minutes) – Panel discussion	Spain)
	Panel discussion on key questions related to	Jonathan Ross (Bristows,

European Patent Lawyers Association



	plausibility and how these questions are handled in different national jurisdictions, particularly focusing on the G2/21 decision and how the different jurisdictions are applying this to the apixaban case. So far, such key questions identified include the relevance of the patent bargaining principle, what technical teaching needs to be present, and the prevention of speculative applications.	UK) Mzolisi Mtshaulana (Vondst, the Netherlands) Nora Brathiem (Wikborg Rein, Norway) Louis Bidaine (Stibbe, Belgium - Moderator)
15.00	Coffee break (0.30)	-/-
15.30	 Life Sciences Round-up – now and future (1.00) The proposed EU "pharma package" (part 1): proposal for unitary SPCs The proposed EU "pharma package" (part 2): the "new" Bolar exemption SPC manufacturing waiver under Regulation (EU) 2019/933 AI – developments in 2023, plus future questions such as impact on legal standards (POSITA, inventive step etc.) 	Imogen Ireland (Hogan Lovells, UK - Chair) Laura Di Tecco (Jacobacci Avvocati, IT) Pietro Dettori (Bird & Bird, IT) Barbara Mooij (Brinkhof, NL) Valentin Wagner (Hoyng Rokh Monegier, DE)
16.30	Closing	Cordula Schumacher, President of EPLAW

Special thanks to the organizing committee:

Lorenzo Battarino, Sven Krause (co-chairs of the committee), Clara Berrisch, Louis Bidaine, Nadine Bleach, Alex Calver, Chiara Centola, Mariagiulia De Rosa, Pietro Dettori, Laura Di Tecco, Daniel Down, Sian Edmonds, Ettore Fassina, Federica Franchetti, Dirk Henderickx, Imogen Ireland, Federico Manstretta, Inés Molina, Barbara Mooij, Mzolisi Mtshaulana, Giulia Pasqualetto, Ethan Plumb, Jonathan Ross, Nora Sandvik Bratheim, Ronja Schregle, Sab Singh, Joscha Torweihe, Jemma Trainor, Max von Leitner, Valentin Wagner, Matthew White